Lv1
50 积分 2026-03-06 加入
[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)]
3小时前
已完结
Toward a Biomarker of Oxidative Stress: A Fluorescent Probe for Exogenous and Endogenous Malondialdehyde in Living Cells
1天前
已完结
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
6天前
已完结
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
6天前
已完结
Treatment-Related Diarrhea in Patients With Cancer
6天前
已关闭
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer
6天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
10天前
已完结
First-line fovinaciclib versus placebo combined with aromatase inhibitor for advanced breast cancer: A randomized, double-blind phase 3 study
17天前
已关闭
Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials
17天前
已关闭
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
17天前
已完结
皖公网安备34019202002308
